Ipsen company profile

IPN · Euronext Paris · EUR

Compare Ipsen
€164.10Change from previous close: −1.97%Absolute change: −€3.30

Close · November 17, 2026

Company profile

Ipsen has 5,535 employees and is headquartered in Paris, France.

Ipsen is best known for Somatuline, Dysport and Decapeptyl, with Cabometyx, Onivyde, Bylvay, Iqirvo and Sohonos also among its marketed or developed medicines. The biopharmaceutical group develops and commercializes treatments in oncology, rare disease and neuroscience, selling them in North America, Europe and other international markets. Its pipeline includes candidates in Phase III trials for follicular lymphoma and pediatric low-grade gliomas, as well as earlier-stage programs in solid tumors and aesthetic indications.

In the fiscal year ended December 2025, Ipsen reported revenue of EUR 3.9 billion, up 9.9% from the previous year, and net income of EUR 443.5 million. The company employed 5,535 people and is headquartered in Paris, France, where it was founded in 1929.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Country
France
Headquarters
70 rue Balard, 75015, Paris
Employees
5,535
Chief executive
David Loew
Founded
1929
Fiscal year
January - December
Listing
IPN · Euronext Paris
Currency
EUR
ISIN
FR0010259150
Website
ipsen.com

Ipsen and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
IpsenIPNFrance$14.2B5,53527.4%25.5
Swedish Orphan BiovitrumSOBISweden$16.27B2,20730.9%25.0
H. LundbeckHLUN.ADenmark$8.49B5,00024.4%14.2
HaleonHLNUnited Kingdom$40.15B24,53523.5%19.3
Sandoz GroupSDZSwitzerland$43.57B20,0009.3%72.3
Laboratorios Farmaceuticos RoviROVISpain$3.93B1,95020.2%17.4

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Ipsen with its competitors